奈莫利珠单抗在特应性皮炎与结节性痒疹中快速改善瘙痒:3期研究事后分析
该事后分析纳入ARCADIA 1/2(特应性皮炎,N=1728)和OLYMPIA 1/2(结节性痒疹,N=560)四项随机对照3期试验,评估奈莫利珠单抗治疗前14天瘙痒与睡眠改善。结果显示,第2天瘙痒应答率即显著优于安慰剂,并持续增至第14天,睡眠亦早期改善。
要点
- 奈莫利珠单抗第2天即显著改善中重度特应性皮炎和结节性痒疹瘙痒。
- 第2天瘙痒应答率差值:特应性皮炎10.7% vs 2.9%,结节性痒疹17.2% vs 3.7%。
- 睡眠障碍应答率亦在第2天起优于安慰剂,提示快速综合获益。
核心结论
- 奈莫利珠单抗可在治疗第2天快速改善中重度特应性皮炎和结节性痒疹患者的瘙痒与睡眠障碍。
研究设计与样本
- 对ARCADIA 1和2(特应性皮炎,N=1728)及OLYMPIA 1和2(结节性痒疹,N=560)四项随机对照3期试验进行事后分析。
- 患者每日报告瘙痒强度和睡眠障碍,计算奈莫利珠单抗组与安慰剂组应答者比例差异。
主要发现
- 特应性皮炎汇总数据中,第2天PP-NRS应答率差值(奈莫利珠单抗vs安慰剂)为10.7% vs 2.9%(95%CI 5.6-10.1;p<0.0001),并持续增至第14天。
- 结节性痒疹汇总数据中,第2天PP-NRS应答率差值为17.2% vs 3.7%(95%CI 6.8-16.7;p<0.0001)。
- 特应性皮炎汇总数据中,第2天SD-NRS应答率为9.9% vs 4.6%(95%CI 2.8-7.7;p=0.0001)。
- 结节性痒疹汇总数据中,第2天SD-NRS应答率为13.4% vs 4.3%(95%CI 4.0-13.0;p=0.0013)。
- 各单项研究结果与汇总数据一致。
关键数值与推荐
- 瘙痒应答定义为PP-NRS较基线改善≥4分;睡眠应答定义为SD-NRS较基线改善≥4分。
临床怎么用
- 对于中重度特应性皮炎和结节性痒疹患者,奈莫利珠单抗可作为快速控制瘙痒和改善睡眠的治疗选择。
- 治疗早期(第2天)即可评估瘙痒应答,有助于医患沟通和坚持治疗。
局限性
- 为事后分析,证据级别低于预设主要分析。
- 仅评估治疗前14天的短期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Itch is the most burdensome symptom in atopic dermatitis (AD) and prurigo nodularis (PN) and is associated with significant psychological distress, sleep deprivation and impaired quality of life. Achieving rapid control of itch is expected to minimize symptomatology and disease burden. Nemolizumab, which targets the interleukin 31 (IL-31) pathway, rapidly relieved itch in Phase 2 trials; thus, a post hoc analysis of four pivotal randomized controlled clinical trials of nemolizumab in AD and PN was performed to further evaluate the improvement of itch over the first 14 days of therapy. METHODS: Data from ARCADIA 1 and 2 in AD (N = 1728) and OLYMPIA 1 and 2 in PN (N = 560) were analysed. Patients reported itch intensity and sleep disturbance daily. Differences in the proportion of itch and sleep responders (patients with ≥4-point improvement from baseline in peak pruritus numerical rating scale [PP-NRS] or sleep disturbance [SD-NRS] score) between nemolizumab and placebo groups were calculated. RESULTS: Nemolizumab rapidly reduced itch in AD (ARCADIA 1 and 2), with a difference versus placebo in PP-NRS responders apparent by Day 2 (pooled data: 10.7% vs. 2.9%; 95% CI: 5.6-10.1; p < 0.0001) that steadily increased through Day 14. Nemolizumab also reduced itch rapidly in PN (OLYMPIA 1 and 2); a difference versus placebo occurred by Day 2 (pooled data: 17.2% vs. 3.7%; 95% CI: 6.8-16.7; p < 0.0001). Early improvement (Day 2) was also observed in sleep in nemolizumab-treated patients. In pooled analyses in AD, 9.9% (nemolizumab) versus 4.6% (placebo; 95% CI: 2.8-7.7; p = 0.0001) were SD-NRS responders and in PN, 13.4% versus 4.3% (95% CI: 4.0-13.0; p = 0.0013). Itch and sleep response data in individual studies were consistent with the pooled data. CONCLUSIONS: This analysis confirms previously reported data that nemolizumab relieves itch and sleep disturbance by Day 2 in patients with moderate-to-severe AD and PN, indicating that targeting the IL-31 pathway presents an important way to achieve rapid itch response. People with skin diseases such as atopic dermatitis and prurigo nodularis experience itch, which can be severe and can interfere with their daily lives with missed school or work days and psychological well‐being impairment, especially when the itching lasts for a long time as is often the case with these diseases. Itching can also make it hard to sleep. A medicine that quickly stops itching can help people with atopic dermatitis and prurigo nodularis to feel better. Nemolizumab is a medicine that is approved to treat atopic dermatitis and prurigo nodularis and it works fast to stop itching. This study looked at data from four clinical studies of nemolizumab, focusing on how itch changed during the first 14 days of treatment. Patients in the studies who had atopic dermatitis or prurigo nodularis recorded daily in diaries how much itch they felt and how they slept. The researchers found that nemolizumab started working to control itching in just 2 days and patients also slept better. Less itching and better sleep may improve well‐being in people with atopic dermatitis and prurigo nodularis.
引用
- Ständer S, Elmariah SB, Kwatra SG, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. J Eur Acad Dermatol Venereol. 2025. PMID: 41401055. doi:10.1111/jdv.70250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。